RF vs SPRY
RF (RF) versus ARS Pharmaceuticals, Inc (SPRY) — a side-by-side from cached financials, not a winner call.
RF (RF) common stock.
ARS Pharmaceuticals, Inc (SPRY) is a biotechnology company listed on NASDAQ.
RF does not have a complete income-statement cache yet.
Latest reported SPRY revenue for 2024-12-31 was $89.1M. Net income was $8.0M. Revenue was up 297063.3% from 2023-12-31 to 2024-12-31. SPRY currently screens at market cap $983.1M.
RF currently screens at market cap $0. SPRY currently screens at market cap $983.1M.
Not investment advice. Open the RF and SPRY stock pages for the full models.
Not investment advice.